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Abstract 
Poor drug solubility and dissolution rate remain to be one of the major problems facing 
pharmaceutical scientists, with approximately 40% of drugs in the industry categorised as practically 
insoluble or poorly water soluble. This in turn can lead to serious delivery challenges and poor 
bioavailability. The aim of this research was to investigate the effects of the surfactants, poloxamer 407 
(P407) and caprol® PGE 860 (CAP) at various concentrations (0.1, 0.5, 1 and 3% w/v) on the 
enhancement of the dissolution properties of poorly water-soluble drug, naproxen using in-situ 
micronisation by solvent change method and freeze drying. The extent at which freeze drying influences 
the dissolution rate of naproxen microcrystals is investigated in this study by comparison with desiccant 
drying. All formulations were evaluated and characterised using particle size analysis and morphology, in 
vitro dissolution studies, differential scanning calorimetry (DSC) and Fourier transform infra-red (FT-IR) 
spectroscopy. An increase in poloxamer 407 concentration in freeze dried formulations led to 
enhancement of drug dissolution compared to desiccator dried formulations, naproxen/caprol® PGE 860 
formulations and untreated drug. DSC and FT-IR results show no significant chemical interactions 
between drug and poloxamer 407, with only very small changes to drug crystallinity. On the other hand, 
caprol® PGE 860 showed some interactions with drug components, alterations to the crystal lattice of 
naproxen and poor dissolution profiles using both drying methods, making it a poor choice of excipient. 
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Introduction 
Many newly developed active drug molecules demonstrate considerable lipophilicity, hence low 
solubility, low dissolution rate, and poor bioavailability. This can be a major formulation challenge, 
especially for orally administered drugs (1-3), where more than 40% of new compounds need formulation 
optimisation to overcome poor oral absorption because they fall under Biopharmaceutical Classification 
System (BCS) class II (low solubility, high permeability) and/or class IV (low solubility, low 
permeability) (4-5).  
Various techniques or approaches are available to improve the solubility and dissolution of poorly soluble 
drugs. These include, but are not limited to: 1) physical approaches such as particles size reduction, solid 
dispersion, use of surfactants; 2) chemical modification such as salt formation; 3) nanotechnology, such 
as nanoparticles (6); and 4) liquisolid technique (7-9). 
Physical modifications often aim to increase surface area, solubility and wettability of drug particles and 
typically focus on particle size reduction. Particle size reduction is one of the oldest strategies for 
improving drug bioavailability (10), where it is well known from the Noyes-Whitney equation that the 
dissolution rate of an active pharmaceutical ingredient is proportional to the available surface area. Hence, 
a decrease in particle size and corresponding increase in the surface area of the particles, increases the 
dissolution rate (10-11).  
One of the effective and increasingly used techniques for achieving particle size reduction is by 
micronisation (12-13). Micronisation is a term used to describe size reduction, where the resulting particle 
size distribution is less than 10 microns (14-15). A number of methods have been suggested to produce 
micron sized particles such as milling and grinding (16-17), supercritical fluid techniques and spray 
drying.   
Milling processes do not always result in significant enhancement of drug dissolution rate (16). The 
milled particles have a tendency to agglomerate as a result of their hydrophobicity, thus reducing their 
available surface area (18). It is also difficult to obtain uniform fine particles and control the dose of the 
drug (17).   In addition to this, micronisation using milling techniques are not efficient due to their high 
energy input, and disruptions in the crystal lattice can cause physical and chemical instability (19-20). 
Supercritical fluid technology is environmentally friendly and suitable for mass production, however, 
requires specially designed equipment and is more expensive (21).  
In-situ micronisation is a promising particle engineering technique, it is a one-step process where micron 
sized crystals are obtained by controlled crystallisation without the need for any further particle size 
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reduction (15, 22-23). This technique uses common equipment (refer to section 2.2), whereas other 
micronisation techniques like milling, supercritical fluid and spray drying are more complicated and 
require specialised containment facilities which could be expensive and labour intensive (15).  
 In recent years, in-situ micronisation using solvent change (anti-solvent) method has been found to be an 
effective way to produce micronised drug particles (13). This method allows the micronisation of a drug 
substance along with surface modification using hydrophilic polymers which will in turn enhance wetting 
properties and increase the stability of microcrystals (15). Rasenack and Muller (22) looked at dissolution 
rate enhancement by in-situ micronisation using a rapid solvent change process, the results showed 
markedly enhanced dissolution rate of the drug powders. They also found that the particle size is more 
uniformly distributed and the powder is less cohesive. In another study Varshosaz et al. (19) found that 
in-situ micronisation using solvent change method reduced the particle size of gliclazide by 
approximately 50 times and that the dissolution efficiency at 15 minutes was increased about 4 times.  A 
study investigated the dissolution rate enhancement of tolbutamide by in-situ micronisation, and reported 
the dissolution rate efficiency of tolbutamide microcrystals to be increased approximately 8 times (13). 
The aim of this study was to apply in-situ micronisation technique using the solvent change method to 
enhance the dissolution properties of poorly water-soluble drug naproxen. The effects of the polymers 
poloxamer 407 and caprol® PGE 860 used as stabilisers was investigated. In addition to this, a number of 
studies have shown freeze drying to enhance dissolution rate of poorly soluble drugs (24-26).  Therefore, 
the extent to which freeze drying influenced the dissolution rate of naproxen was also studied.  
2.  MATERIALS AND METHODS 
2.1. Materials 
Naproxen (NAP; BN. 027K003, Roche-Syntex S.A. de C.V., Mexico) with mean particle size of 355µm 
and molecular weight (Mw) of 46.07 g/mol, was used as the model hydrophobic drug throughout the 
experiment. Poloxamer 407 (P407; Pluronic F127) (BN. 027K003, Sigma – Aldrich company Ltd, UK), 
and caprol® PGE 860 (CAP; BN. 061213-8, Abitec, USA, given as a gift) were selected as the surfactants 
for investigation in this study. The chemicals ethanol (Mw: 46.07 g/mol) and methanol (Mw: 32.04 
g/mol) (Fisher Scientific, UK) were of analytical grade. 
2.2. Microcrystallisation of naproxen: In-situ micronisation 
In-situ micronisation was used following the solvent change method (22). This process involved rapidly 
mixing the prepared naproxen solution with a specific concentration of surfactant solutions, being either 
poloxamer 407 (P407) or caprol® PGE 860 (CAP) (stabilising agents). Initially 1% w/v pure naproxen 
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crystals were dissolved in a required volume of ethanol (as solvent), in 250 ml (for P407 study), and in 
500 ml (for CAP study). The stabilising agents were dissolved in a required amount of distilled water (as 
non-solvent) (up to 100 ml for P407, and up to 200 ml for CAP). Four different concentrations (0.1, 0.5, 1 
and 3% w/v) of the two surfactants were chosen (Table 1). Both naproxen and surfactant solutions were 
then sonicated for approximately 30 minutes using an Ultrasonic Cleaner (Hilsonic, UK). Using a 10ml 
syringe (B-D Plastipak, UK), a total volume of 25 ml of 1% w/v naproxen was added as 5ml (x5) aliquots 
every 2 minutes to each concentration of both surfactants (P407 and CAP).  Additionally, two samples of 
naproxen (F1 and D1) were tested without the addition of either P407 or CAP, and were added to 100 ml 
of fresh distilled water in the same manner. The newly formed suspensions were continuously stirred for 
10 minutes using a magnetic mixer (Ikamag RCT, UK). The preparations were then centrifuged for 10 
minutes at a speed of 20,000 rpm and supernatants were decanted before being dried by either freeze 
drying via VirTis Benchtop Freeze Dryer (Biopharma, USA), or desiccator drying using desiccators with 
silica gel.  
Insert Table 1 
 
2.3. Evaluation of naproxen microcrystals  
2.3.1. Microscopic examination of naproxen microcrystals  
Morphological assessment of the 19 samples prepared from the in-situ micronisation technique was 
undertaken using an Olympus - BH2 polarized light microscope (Optivision Ltd. Japan) fitted with a 
digital camera (AxioCam MRc-Zeiss, UK), and an image analyser (AxioVision, vs4.4., Carl Zeiss). The 
samples were observed with a 20x objective lens and a 10x eyepiece lens.  
2.3.2. Particle size analysis 
The size distribution of the microcrystals produced was measured using a Swift M4000D optical 
microscope (Swift optical instruments, San Jose, California, America), where more than 100 particles 
were used. Also, the microscope used a calibrated British standard eye piece graticule. 
2.3.3. In vitro dissolution testing 
The dissolution rate of all naproxen microcrystals was carried out under sink conditions using the United 
State Pharmacopoeia paddle apparatus (Erweka DT 6, Heusenstamm, Germany). Samples of 30mg were 
placed into 1L of distilled water maintained at 37 ± 0.5oC, and the stirring speed employed was 100rpm. 
Samples of 10ml were withdrawn periodically (5, 10, 15, 20, 30, 40, 50 and 60 minutes) and replaced 
with the same volume of the fresh dissolution medium. The amount of drug released was determined by 
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initially measuring the absorbance at 271 nm using a UV/VIS spectrophotometer (Campsec M501 Single 
Beam Scanning, Cambridge, UK) and applying the calibration equation. The results are the mean and 
standard deviation of three replicates. 
 
2.3.4. Differential scanning calorimetry (DSC) 
Thermal analysis of all naproxen microcrystals was performed using a differential scanning calorimeter 
(DSC Q1000, TA instruments, England) equipped with a DSC refrigerated system using liquid nitrogen. 
Approximately 3-6 mg samples were individually crimped into hermetically sealed aluminium pans (TA 
instruments, England). Samples were scanned at a ramp rate of 10oC/ minute and heated between 0.00oC 
– 200.00oC.   
2.3.5. Fourier-transform infrared spectroscopy (FT-IR) 
Fourier transform infrared spectra for all naproxen microcrystals were obtained using IR 
spectrophotometer (PerkinElmer FT-IR System, Spectrum BX, PerkinElmer, UK). The spectra were 
recorded over a scanning range of 550 to 4000 cm-1, a resolution of 4.0 cm-1 was maintained and the 
number of scans used was 10.  
 
2.4. Statistical analysis  
One-way analysis of variance (ANOVA) was carried out to analyse the dissolution test results using SPSS 
vs16.0 software package for windows (SPSS Inc. Chicago, USA). Comparison between the two means 
was determined following either a post-hoc Scheffè test (for freeze dried naproxen/poloxamer 407 
samples) or the Games-Howell test (for freeze dried naproxen/caprol® PGE 860 samples). Additionally, 
an independent T-test was performed to verify the significance between the two methods of drying (freeze 
drying and desiccator drying) at all concentrations. All data were produced at a 95% confidence interval 
and differences were considered as significant when probability (ρ) was < 0.05.  
 
3. RESULTS AND DISCUSSION  
3.1. Particle size and morphology 
The commercial drug (U1) appeared as smooth white crystals, representing a high degree of crystallinity 
(Fig. 1), this was confirmed using DSC. Particle sizes were broadly distributed across ranges from 7.5 µm 
to 41.37 µm. This was expected as U1 did not undergo in-situ micronisation, which would have yielded a 
tighter and more symmetric particle size distribution (22). For freeze dried pure naproxen (F1), in-situ 
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micronisation generated smaller, more homogenous microcrystals, showing areas of both white crystals 
and dark amorphous particles. Approximately 54% of F1 microcrystals were 7.5 µm in size; a 4.5- fold 
decrease in size from U1, which showed only 12% of microcrystals having 7.5 µm in size. 
Freeze dried samples containing P407 as the surfactant, showed a decrease in particle size with an 
increase in P407 concentration. The upper quartile for F3 (naproxen/ 0.5% w/v P407) microcrystals was 
12.6 µm and was considerably lower than that observed for F1 (33.4 µm). For F4 (naproxen/ 1% w/v 
P407), 100% of microcrystals were 7.5µm in size.  
A similar pattern was seen for desiccator dried samples containing P407, where an increase in P407 
concentration lead to a decrease in particle size, and an increase in homogeneity. However, the reduction 
in the size of the crystals was not as pronounced for desiccator dried samples as it was for freeze dried 
samples. Rasenack et al. (27) stated that the strength at which the surfactant is adsorbed onto the surface 
of the crystal is determined by the method of drying. It can therefore be understood that certain processes 
involved in freeze drying, such as rapid sublimation, results in a more intense adsorption of P407 on the 
surface of crystals ensuring the stability of particles (28). Additionally, by preventing aggregation and 
ensuring homogeneity, freeze drying is responsible for delivering particles of a small size distribution if 
this drying process used to dry initially controlled sized particles. This was in contrast to the results seem 
by Talari et al. (18), where in-situ micronisation was used through a pH change method, and found no 
significant change in particle size distribution of microcrystals before and after freeze drying. This 
suggests that it is in fact a combination of solvent change method and freeze drying that influence 
naproxen crystals’ properties. Varshosaz et al. (5) found that the highest dissolution rate and smallest 
particle size of piroxicam microcrystals were observed using the solvent change method when compared 
to pH shift method.  
In terms of morphology. The dark amorphous regions seen for F1 are also observed for desiccator dried 
samples (D3 and D5, Fig. 1), and become more pronounced with the addition of P407 and with an 
increase in its concentration, as represented by the photomicrographs of D3 and D5. However, for freeze 
dried samples, the addition of increased amounts of P407, as seen for F5, results in a return to a more 
crystalline state that can explain the lower drug released from this formula, refer to Fig. 2a.  
Microcrystals containing caprol® PGE 860 (CAP) show small particle size, increased homogeneity and 
very narrow particle size distribution. For 0.1 and 0.5% w/v CAP, identical particle sizes and 
homogeneity for both freeze dried and desiccator dried samples were seen (Inter Quartile Range = 
1.5µm). Photomicrographs for D8 and F9 (Fig. 1) show the existence of a polymorphic crystal form with 
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needle-shaped appearance. Rasenack et al., (1) reported that these crystals are thermodynamically 
unstable and galenically unacceptable due to their felted nature.  
Insert Fig. 1 
3.2. In vitro dissolution testing  
Dissolution profiles of freeze dried (F2 – F9) and desiccator dried (D2 – D9) naproxen/surfactant 
microcrystals, prepared using in-situ micronisation, are illustrated in Fig. 2a – 2d and are represented as 
percentage drug release versus time. Dissolution profiles of pure naproxen microcrystals (F1 and D1) 
(crystallised using in-situ micronisation in the absence of surfactants) and untreated naproxen (U1) (did 
not undergo in-situ micronisation) are also included these figures.  
As shown in Fig. 2a, the data revealed that untreated naproxen (U1) had poor dissolution profiles 
compared to freeze dried pure naproxen microcrystals (F1) and naproxen/P407 microcrystals (F2 – F4), 
with only 18±8.85% drug released after 5 minutes and 70±3.77% drug release after 60 minutes for U1, 
compared with a burst release of 81.07±1.92% and 77.45±7.03% after 5 minutes for F1 and F3 
respectively, achieving over 90% drug release within 15 minutes. The highest drug release was seen for 
F4, with 99±2.77% after 5 minutes (5.5 times greater than U1). Similar observations were detected for 
desiccator dried samples (Fig. 2b), with an enhanced dissolution rate of naproxen/ P407 microcrystals (D2 
– D5) when compared to untreated naproxen, with the dissolution of the microcrystals after 5 minutes 
being 35±7.00% (D2) and 84.76±4.68% (D5), which is 1.9 to 4.7 times greater than that of untreated 
naproxen (U1). However, this was not as pronounced as those reported for the freeze dried samples and 
generally showed higher standard deviations over the course of 60 minutes. 
From Fig. 2a and 2b, it is also evident that the higher concentrations of P407 (both freeze dried and 
desiccator dried) yielded an improved dissolution rate over the course of 60 minutes. For example, at 30 
minutes, the drug release increased from 79±0.57% to about 100% (F2 – F4) and from 64±1.11% to 
95±5.63% (D2 – D5). The low percentage drug release detected at lower poloxamer concentrations show 
that microcrystals have not been sufficiently wetted by the surfactant.  
In general, when comparing the two drying methods used, it is evident that all freeze dried formulations 
showed improved drug dissolution than that of desiccator dried formulations. The total drug release for 
freeze dried formulations was observed with F4 after only 10 minutes. However, the same formulation 
desiccator dried (D4) showed a considerably lower drug release of 67±7.72% (ρ < 0.05). The highest 
percentage drug release for desiccator dried formulations was 96.72±6.19% for D5, achieved after 60 
minutes of dissolution. The increased dissolution rate with increased P407 concentration for freeze dried 
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microcrystals, could partly be explained by the presence of amorphous regions (29) as shown in Fig.1. 
The decreased dissolution rate seen for F5, showing only 65% ± 1.59 after 60 minutes is reflected by the 
photomicrograph seen in Fig. 1, with increased crystalline regions.   
Insert Fig. 2 
The effect of CAP on the dissolution rate of naproxen shows less encouraging characteristics for its 
potential use as a dissolution enhancer. Fig. 2c and d show that, in contrast to P407, an increase in caprol® 
PGE 860 concentration results in a decrease in the dissolution rate of naproxen microcrystals. For 
example, drug release of freeze dried microcrystals after 10 minutes decreased as follows: 57±3.68%, 
15±1.64%, 10.27±1.08% and 7.18±0.04% for F6, F7, F8 and F9, respectively. This can be attributed to 
the highly viscous physical nature of CAP, whereby upon addition to an aqueous medium, a viscous 
diffusion layer is formed causing the extremely low passage of drug into solution (30).  Ultimately, the 
naproxen microcrystals are not adequately wetted and the dissolution rate constant is lowered even though 
the solubility may have been higher (31).  A study by Akinlade et al. (32) described CAP to be a poor 
choice of excipient, and was attributed to its highly viscous nature.  
The dissolution rate of naproxen/CAP is significantly lower (ρ<0.05) than that of pure naproxen 
microcrystals (F1) and naproxen/P407 microcrystals for both freeze dried and desiccator dried samples. 
For example, drug release for F3 (0.5% w/v poloxamer 407 freeze dried) after 10 minutes was 87±6.35%, 
showing sufficient wetting and rapid dissolution of the microcrystals and drug release was 81% for F1 
(pure naproxen microcrystals freeze dried). In comparison to this, only 16±1.65% of drug released after 
10 minutes for F7 (0.5% w/v CAP) (ρ<0.05).  
The results imply that naproxen/P407 microcrystals and freeze drying show enhanced dissolution 
properties than that of naproxen/CAP microcrystals and desiccator drying. The highest percentage drug 
release for naproxen/poloxamer microcrystals was for F4 and was achieved after 10 minutes. However, 
the highest percentage drug release for naproxen/CAP microcrystals was 91±2.00% (F6) and was 
achieved after 60 minutes’ dissolution. The results could also indicate that P407 preparations had a 
greater presence on the surface of naproxen microcrystals than CAP., which would result in greater 
reduction of the surface tension between the hydrophobic naproxen microcrystals and the aqueous 
medium. Consequently, the energy within the system is reduced allowing individual naproxen particles to 
become dispersed in the aqueous solution. Hence, the dissolution of these microcrystals is more rapid due 
to the increase in specific surface area of naproxen microcrystals. In a study by Steckel et al (33), the 
physico-chemical properties of in-situ micronised fluticasone-17-propionate (FP) and jet milled FP were 
compared, and found the milled drug to possess amorphous areas on its surface due to the energy input of 
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the milling process. However, in-situ micronised drug was found to be less susceptible to chemical 
degradation or alternation in physical properties with improved followability and dispersibility.  
 
 
3.2. Differential scanning calorimetry (DSC) 
The prepared samples (untreated naproxen, pure naproxen microcrystals, naproxen/P407 and 
naproxen/CAP microcrystals) were examined using DSC, the melting point (Tm) and enthalpy of fusion 
are presented in Table 2, and the thermograms produced are shown in Fig. 3A - G 
 
Insert Table 2 
 
According to the British Pharmacopeia (34), the melting point of pure untreated naproxen ranges between 
154 to 158oC. From Table 2 and Fig. A and B, pure naproxen showed a single sharp melting peak (Tm) at 
about 157.70oC and ΔH of 134.3 J/g for freeze dried microcrystals (F1), this was slightly lower than the 
value obtained for desiccator dried microcrystals (D1) with a Tm of 158.51oC and ΔH of 145.7 J/g. The 
sharp peak is characteristic of naproxen’s crystalline nature, and is similar to that obtained by Dixit et al. 
(35) and Akbari et al. (36) with a sharp Tm at about 154oC, and by Elkordy et al. (37) with the 
endothermic peak at 158.9oC for pure untreated naproxen. The melting point of P407 as stated in the 
British Pharmacopeia is about 50oC (34). Therefore, the short peaks observed at the beginning of the 
heating procedure (Fig. 3C and D) are related to the Tm of P407, with a value of 50.82oC for 0.5% w/v 
P407 and 51.20oC for 1% w/v P407. The increased intensity seen in Figure 3D is due to the increased 
poloxamer concentration.   
The characteristic endothermic peak for pure naproxen was present in all profiles. However, a slight 
reduction in Tm was seen with the addition of surfactant and with an increase in surfactant concentration. 
For example, the addition of 0.5% w/v P407 reduced the Tm from 157.70oC for pure freeze dried 
naproxen microcrystals, to 156.99oC. The enthalpy of fusion was also reduced from 134.3 J/g to 120.1 
J/g. A further increase in P407 concentration to 1% w/v lead to further reduction in Tm and enthalpy of 
fusion to 155.64oC and 88.51 J/g, respectively. As mentioned previously, in-situ micronisation leads to 
the reduction in surface tension and enhanced wetting properties of poorly water soluble drugs as a result 
of the stabilising agent (in this case P407) being adsorbed on to the drug particles (5, 15). This would 
therefore explain the reduced Tm seen with increased poloxamer concentration and goes hand in hand 
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with the dissolution results obtained in this study, and with the morphology photomicrographs (Fig.1) 
mentioned previously.  
Insert Fig. 3 
Even though the Tm of naproxen decreases with an increase in P407 concentration, this slight reduction 
remains consistent with literature values mentioned previously, and the thermograms for P407 containing 
samples show characteristic features of both the naproxen and P407, this could therefore indicate the 
absence of significant chemical interactions between the drug and polymer. Similar observations were 
found in a number of studies for different drugs/polymers and was also explained as there being no 
interaction between the two (5, 9, 13, 38). 
In addition, the intense reduction in enthalpy of fusion has been considered by a number of studies to be 
related to the loss of drug crystallinity (39-40). It has also been reported that the reduction in microcrystal 
particle size and the small amount of stabiliser may affect the reduction in enthalpy and that the 
precipitated drug is sterically stabilised against crystal growth by adsorbed polymer. Hence, the surface 
energy and consequently the enthalpy of the system is lowered (5, 19). Dixit et al. (40) looked at 
enhancing the solubility and dissolution of indomethacin by freeze drying, they found that the dissolution 
of freeze dried crystals was increased and was thought to be linked to the better wettability and reduction 
in particle size with increasing surface area of freeze dried crystals. Therefore, it can be stipulated that the 
improved dissolution properties documented in this study for naproxen/ P407 may not entirely be due to 
changes in drug crystallinity, but could be due to the improved wetting properties and reduction in 
particle size as a result of the combined effect of in-situ micronisation, freeze drying and the type of 
surfactant used. 
The DSC thermogram produced for caprol® PGE 860 (Fig. 3E and F) contained the recognisable 
naproxen melting peak (Tm) at 153.52oC, with enthalpy of fusion of 98.83 J/g for F6, and a Tm at 
153.29oC for D6, with a much lower enthalpy of 83.05 J/g. Interestingly, these values were not consistent 
with literature values for naproxen Tm, and the enthalpy of fusion was even lower than that obtained using 
P407. Additionally, this may be due to different arrangement of drug molecules in the crystal lattice.   
Increasing the concentration of CAP further to 1% w/v, resulted in an alteration in the thermogram 
profile, with a marked broadening and reduction in the intensity of the naproxen endotherm, which was 
shifted to a Tm of 147.95oC, and the enthalpy of fusion was considerably reduced to 5.028 J/g, which is a 
96.5% reduction in enthalpy compared to desiccator dried pure naproxen microcrystals (D1).  
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This would imply the possibility of interactions between the components (41-42) and/or polymorph 
formation.  This coincides with the dissolution results that show marked reduction in dissolution rate with 
an increase in CAP concentration. This could also be due to the highly viscous nature of caprol® PGE 
860 (32), whereby upon addition to an aqueous medium, a viscous diffusion layer is formed causing the 
extremely slow passage of drug into solution (30). Ultimately, the naproxen microcrystals are not 
adequately wetted and the dissolution rate constant is lowered even though the solubility may have been 
higher (31).  
3.3. Fourier-transform infrared spectroscopy (FT-IR) 
FT-IR spectroscopy was used to study any possible interactions between the model drug naproxen and 
stabiliser (being either poloxamer 407 or caprol® PGE 860), and to analyse any possible changes in 
chemical structure. The spectra of all samples are shown in Fig. 4. 
 
The crystal structure of naproxen exists as a trimolecular catemer (44). Therefore, the spectra for pure 
untreated naproxen, U1, (Fig. 4A) shows the typical quartet of bands stretching between 1723 cm-1 and 
1602 cm-1, which is characteristic of carbonyl (-C=O) stretching vibrations (37, 42-43). Peaks at 1723 cm-
1 and 1681 cm-1 attributed to non-hydrogen bonded carbonyl (-C=O) stretching and hydrogen bonded 
carbonyl stretching of the catemer respectively (44). The intensity of the vibrational bands at 1723 cm-1 is 
more dominant because most of the naproxen molecules are not engaged in hydrogen bonding (44-45). 
The spectra for both F1 and D1 show a small shift at the non-hydrogen bonded carbonyl group -C=O 
from 1723 cm-1 to 1726 cm-1, which could indicate changes in hydrogen bond characteristics due to the 
removal of moisture exerted by either freeze drying or desiccator drying (46). Similar shift of the 
carbonyl stretch to higher energy was found by Islam et al. (46) and was attributed to the evaporation of 
solvent water. 
Insert Fig. 4 
From Fig. 4A, B and C, it can be concluded that the typical quartet of bands of naproxen carbonyl 
stretching were present in all naproxen/P407 spectra, with only small shifts in wavenumber with the 
addition of P407, for example, the addition of 0.1% w/v P407 lead to bathochromic shift at the hydrogen 
bonded carbonyl stretching band from 1680 cm-1 (pure untreated naproxen) to 1683 cm-1, and from 1723 
cm-1 to 1725 cm-1 at the non-hydrogen bonded carbonyl stretching band. Interestingly, further increases in 
P407 concentration to 1 and 3% w/v lead to the return of wavenumber back to its original value of 1680 
cm-1 and 1723 cm-1. These findings indicate that there may be some degree of hydrogen bonding 
interactions between the drug and polymer (39). The bonding is thought to occur between the carboxylic 
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acid functional group of naproxen and the polyoxyethylene chain of P407 (47-48). It has been reported by 
Anderson et al. (49) that hydrogen bonding leads to a decrease in carbonyl stretching frequency, this 
would explain the small hypsochromic shift seen in this study with an increased P407 concentration and 
the hydrogen bonding is thought to be intermolecular since it is concentration dependent. These findings 
go hand in hand with the dissolution data which shows a decrease in dissolution rate at a poloxamer 407 
concentration of 3% w/v. 
In General, the IR spectrum does not show any additional peaks, and only small shifts in wavenumber 
were seen. This indicates the absence of any significant chemical interactions between naproxen and 
P407, and no or very small alteration to naproxen crystallinity or internal structures (5, 50). It can 
therefore be reported that it is mainly the physical interaction of drug with polymer that is responsible for 
the enhanced dissolution properties recorded (50). 
Analysis of the IR spectra for caprol® PGE 860 microcrystals shows an apparent change in profile noted 
with an increase in CAP concentration. Samples of high CAP concentration e.g. F8 (naproxen/ 1% w/v 
CAP; Fig. 4D) show a broad and less defined -C=O stretching band intensity suggesting a weakening of 
hydrogen bonding and a possible change in chemical structure.  
Albuquerque et al. (51) noted that CAP yields a characteristic stretching vibration band at 1744cm-1 
representing -C=O of the carboxylic groups. This band can be seen developing as the concentration of 
CAP is increased (Fig. 4D). Ultimately, these results combined with literature review suggest that the 
presence of CAP molecules cause a change in the crystal lattice arrangement in naproxen molecules (as 
can be observed as well in Fig. 1 for naproxen microcrystals with CAP, needle crystals), as the intra-
hydrogen bonds between the drug molecules are reduced. This change proves that caprol® PGE 860 is not 
a good choice of excipient to enhance naproxen dissolution.   
 
4. CONCLUSION 
This study demonstrated that in-situ micronisation using the solvent change method had a positive effect 
on dissolution rate enhancement of the poorly water soluble drug, naproxen. The implementation of 
freeze drying showed improvement in the dissolution rate of samples by creating crystals that were 
smaller with a more homogenous size range in comparison to desiccator dried samples. The use of 
poloxamer 407 proved to be a good choice of excipient, serving as a surface active agent, enhancing the 
wetting properties of the microcrystals, yet with only very small changes in drug crystallinity. Caprol® 
PGE 860 on the other hand was found to significantly reduce the dissolution rate of naproxen, showing 
14 
 
some interactions with drug components and alterations to the drug’s crystal lattice arrangement. It can 
therefore be documented that the enhanced dissolution rate seen in this study is due to the combined 
effect of in-situ micronisation using solvent change method, freeze drying and the choice of the polymer. 
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Figure legend 
 
Figure 1. Photomicrographs of untreated naproxen (U1), freeze dried pure naproxen (F1), desiccator dried NAP/ 0.1 
and 0.5% w/v P407 (D3 and D5), freeze dried NAP/ 3% w/v P407 (F5), desiccator dried NAP/ 1% w/v CAP (D8) 
and freeze dried NAP/ 3% w/v CAP (F9). All images were taken using the same magnification (section 2.3.1).  
Figure 2. Dissolution profiles of naproxen/ P407 microcrystals (a) freeze dried (b) desiccator dried, and of 
naproxen/ CAP microcrystals (c) freeze dried (d) desiccator dried. Untreated naproxen (U1) and pure naproxen 
microcrystals (F1 and D1) are included in the profiles. For formulation composition refer to Table 1.  
Figure 3. DSC thermograms of: A) pure naproxen (F1, freeze dried), B) pure naproxen (D1, desiccator dried), C) 
naproxen/0.5% w/v P407 (F3), D) naproxen/ 1% w/v P407 (F4), E) naproxen/ 0.1% w/v CAP (F6), F) naproxen/ 
0.1% w/v CAP (D6), G) naproxen/ 1% w/v CAP (D8). 
Figure 4. FT-IR spectra for naproxen formulations: A) Untreated NAP & NAP microcrystals (freeze dried and 
desiccator dried), B) Untreated NAP and NAP/ 0.1% w/v P407 (freeze dried), C) Untreated NAP and all NAP/ P407 
formulations (freeze dried), D) untreated NAP and NAP/ CAP (0.1 and 1% w/v, freeze dried).  
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List of Tables  
 
Table 1.  Concentrations and drying method of naproxen/surfactant microcrystals produced following in-
situ micronisation 
Drying 
method 
Sample 
Code 
Concentration of 
Naproxen (%w/v) 
Concentration of 
Poloxamer 407 (%w/v) 
Concentration of 
Caprol® PGE 860 
Freeze Drying 
 
 
 
 
 
 
 
F1 1 - - 
F2 1 0.1 - 
F3 1 0.5 - 
F4 1 1 - 
F5 1 3 - 
F6 1 - 0.1 
F7 1 - 0.5 
F8 1 - 1 
F9 1 - 3 
Desiccator 
Drying 
 
 
 
 
 
 
 
 
D1 1 - - 
D2 1 0.1 - 
D3 1 0.5 - 
D4 1 1 - 
D5 1 3 - 
D6 1 - 0.1 
D7 1 - 0.5 
D8 1 - 1 
D9 1 - 3 
Untreated 
Naproxen U1 1 - - 
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Table 2. Results of thermal analysis for naproxen formulations 
Formulation Drying Method 
Melting Point, 
Tm peak (oC) 
Enthalpy of 
Fusion, ΔH  (J/g) 
F1 (Pure 
naproxen) Freeze dried 157.70 134.3 
D1 (Pure 
naproxen) 
Desiccator 
dried 158.51 145.7 
F3 (Naproxen/ 
0.5% P407) Freeze dried 156.99 120.1 
F4 (Naproxen/ 1% 
P407) Freeze dried 155.64 88.51 
F6 (Naproxen/ 
0.1% CAP) Freeze dried 153.52 98.83 
D6 (Naproxen/ 
0.1% CAP) 
Desiccator 
dried 153.29 83.05 
D8 (Naproxen/ 
1% CAP) 
Desiccator 
dried 147.95 5.028 
 
 
